Business Context and Reporting Period
This April 7, 2023 Form 8-K was filed by Vallon Pharmaceuticals, Inc. (Nasdaq: VLON), not by GRI Bio, Inc. It supplements the proxy statement/prospectus for the proposed merger in which Vallon Merger Sub, Inc. would merge with and into GRI Bio, with GRI surviving as a wholly owned subsidiary of Vallon.
The filing relates to Vallon’s virtual special meeting scheduled for April 12, 2023, which Vallon intended to hold and then adjourn to a later date to provide stockholders additional time to consider the reverse stock split proposal.
Financial Metrics and Capital Structure
- The filing does not provide revenue, profit or loss, cash flow, operating margins, debt, liquidity, or other financial performance figures.
- The proposed reverse stock split would be within a range of 1-for-15 to 1-for-40, with the final ratio to be mutually agreed upon by Vallon and the investor before the merger effective time.
Material Changes and Transaction Updates
- Vallon clarified that approval of the reverse stock split is not contingent on approval or consummation of the merger.
- If approved by holders of a majority of Vallon’s outstanding common stock as of the record date, Vallon intends to implement the reverse stock split regardless of whether the merger proceeds.
- On April 5, 2023, Vallon received additional New York Stock Exchange guidance that the reverse stock split proposal would be treated as “routine.” Brokers and nominees may therefore vote uninstructed shares on the proposal at their discretion.
- Stockholders who previously submitted voting instructions may change their vote according to the procedures in the prospectus.
Outlook, Risks, and Other Items
- The merger remains subject to the conditions described in the merger agreement and related SEC materials; this filing does not report consummation or approval of the merger.
- The filing contains customary forward-looking statement and transaction risks, including risks described in Vallon’s periodic SEC filings.
- The filing is supplemental disclosure and is not a substitute for the registration statement, prospectus, or other transaction documents.
- The filing states that it is not an offer to sell or a solicitation of an offer to buy securities. Any securities offering related to the merger would be made only through an applicable prospectus.
Facts Investors Should Verify
- Confirm whether Vallon stockholders approved the reverse stock split and the specific ratio ultimately selected.
- Confirm the date and outcome of the adjourned special meeting.
- Verify whether the proposed Vallon-GRI merger was approved, completed, amended, or terminated.
- Review the registration statement, prospectus, merger agreement, and Vallon’s subsequent SEC filings for transaction consideration, ownership dilution, financing needs, and post-merger capitalization.
- Because the provided filing is issued by Vallon rather than GRI Bio, confirm that it is the intended filing for the requested company and period.